Journey Medical (DERM) GlobeNewswire·2025-03-24 12:30Core Insights - Journey Medical Corporation has launched Emrosi™, a new treatment for inflammatory lesions of rosacea, and the first prescriptions have been filled [2][3] - Emrosi is the lowest-dose oral minocycline available, showing superior clinical outcomes compared to Oracea and placebo while maintaining a comparable safety profile [3] - The FDA approved Emrosi for the treatment of rosacea in November 2024, marking a significant milestone for Journey Medical [3] Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions [7] - The company currently markets eight branded and two generic products aimed at treating common skin conditions [7] - Founded by Fortress Biotech, Inc., Journey Medical is based in Scottsdale, Arizona, and is publicly traded on Nasdaq under the ticker DERM [7] Industry Context - Rosacea is a chronic inflammatory skin condition affecting over 16 million Americans and approximately 415 million people worldwide [6] - The condition often leads to significant impacts on self-esteem and social interactions, with many patients reporting adverse effects on their professional lives [6] - The launch of Emrosi addresses a substantial unmet need in the treatment of rosacea, which is prevalent among adults aged 30 to 50 [6]